Aptahem on the latest news
Aptahem has communicated several positive news lately.
Recently, the company received patent protection in Japan for patent family 2 regarding the drug candidate Apta-1. Encouraging data from research on treatment with Apta-1 in a coronavirus-induced lung injury model was also published, followed by the news that the GMP production of Apta-1 has been completed.
BioStock.